Search Results - "Wynn, Daniel R"

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use by Wynn, Daniel R.

“…Multiple sclerosis (MS) is a chronic progressive neurodegenerative demyelinating disease affecting the central nervous system. Glatiramer acetate (GA;…”
Get full text

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes by Coles, Alasdair J, MD, Fox, Edward, MD, Vladic, Anton, MD, Gazda, Suzanne K, MD, Brinar, Vesna, MD, Selmaj, Krzysztof W, MD, Bass, Ann Doan-Do, DO, Wynn, Daniel R, MD, Margolin, David H, MD, Lake, Stephen L, ScD, Moran, Susan, MD, Palmer, Jeffrey, MS, Smith, M Shelton, PhD, Compston, D Alastair S, MD

“…Summary Background Alemtuzumab is a humanised monoclonal antibody that depletes lymphocytes, causing long-term immunomodulation. In a 3-year, rater-blinded…”
Get full text

Health-related quality of life in multiple sclerosis: effects of natalizumab by Rudick, Richard A., Miller, Deborah, Hass, Steve, Hutchinson, Michael, Calabresi, Peter A., Confavreux, Christian, Galetta, Steven L., Giovannoni, Gavin, Havrdova, Eva, Kappos, Ludwig, Lublin, Fred D., Miller, David H., O'Connor, Paul W., Phillips, J. Theodore, Polman, Chris H., Radue, Ernst-Wilhelm, Stuart, William H., Wajgt, Andrzej, Weinstock-Guttman, Bianca, Wynn, Daniel R., Lynn, Frances, Panzara, Michael A.

“…Objective To report the relationship between disease activity and health‐related quality of life (HRQoL) in relapsing multiple sclerosis, and the impact of…”
Get full text

A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing–remitting or secondary progressive multiple sclerosis by Vollmer, Timothy L, Wynn, Daniel R, Alam, M Shamsul, Valdes, Joaquin

“…Background: Interleukins 12 and 23 (IL-12/23) have been implicated in multiple sclerosis (MS) pathogenesis. This study assessed the efficacy and safety of…”
Get full text

Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis by Fox, Edward, Edwards, Keith, Burch, Gordon, Wynn, Daniel R, LaGanke, Chris, Crayton, Heidi, Hunter, Samuel F, Huffman, Cynthia, Kim, Edward, Pestreich, Linda, McCague, Kevin, Barbato, Luigi

“…Abstract Background The Evaluate Patient OutComes (ClinicalTrials.gov Identifier: NCT01216072) study was conducted in North America to assess patient- and…”
Get full text

Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis by Panitch, Hillel S., Thisted, Ronald A., Smith, Richard A., Wynn, Daniel R., Wymer, James P., Achiron, Anat, Vollmer, Timothy L., Mandler, Raul N., Dietrich, Dennis W., Fletcher, Malcolm, Pope, Laura E., Berg, James E., Miller, Ariel

“…Objective To evaluate the efficacy and safety of DM/Q (capsules containing dextromethorphan [DM] and quinidine [Q]) compared with placebo, taken twice daily,…”
Get full text

Physical Activity Correlates With Neurological Impairment and Disability in Multiple Sclerosis by Motl, Robert W, Snook, Erin M, Wynn, Daniel R, Vollmer, Timothy

“…This study examined the correlation of physical activity with neurological impairment and disability in persons with multiple sclerosis (MS). Eighty…”
Get full text

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis by Radue, Ernst-Wilhelm, Stuart, William H, Calabresi, Peter A, Confavreux, Christian, Galetta, Steven L, Rudick, Richard A, Lublin, Fred D, Weinstock-Guttman, Bianca, Wynn, Daniel R, Fisher, Elizabeth, Papadopoulou, Athina, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…Abstract The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced…”
Get full text

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL by Hutchinson, Michael, Kappos, Ludwig, Calabresi, Peter A., Confavreux, Christian, Giovannoni, Gavin, Galetta, Steven L., Havrdova, Eva, Lublin, Fred D., Miller, David H., O’Connor, Paul W., Phillips, J. Theodore, Polman, Chris H., Radue, Ernst-Wilhelm, Rudick, Richard A., Stuart, William H., Wajgt, Andrzej, Weinstock-Guttman, Bianca, Wynn, Daniel R., Lynn, Frances, Panzara, Michael A.

“…The online version of the original article can be found under doi: 10.1007/s00415-009-0093-1…”
Get full text

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis by Rudick, Richard A, Stuart, William H, Calabresi, Peter A, Confavreux, Christian, Galetta, Steven L, Radue, Ernst-Wilhelm, Lublin, Fred D, Weinstock-Guttman, Bianca, Wynn, Daniel R, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…In this randomized trial involving patients with relapsing multiple sclerosis who had had relapses despite treatment with interferon, natalizumab in…”
Get full text

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL by Hutchinson, M., Kappos, L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Galetta, S. L., Havrdova, E., Lublin, F. D., Miller, D. H., O’Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E.-W., Rudick, R. A., Stuart, W. H., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A.

“…The AFFIRM and SENTINEL studies showed that natalizumab was effective both as monotherapy and in combination with interferon beta (IFNβ)-1a in patients with…”
Get full text

A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-I2 and -23 monoclonal antibody in patients with relapsing―remitting or secondary progressive multiple sclerosis by VOLLMER, Timothy L, WYNN, Daniel R, SHAMSUL ALAM, M, VALDES, Joaquin

Get full text

Natalizumab plus interferon beta-la for relapsing multiple sclerosis by RUDICK, Richard A, STUART, William H, PANZARA, Michael A, SANDROCK, Alfred W, CALABRESI, Peter A, CONFAVREUX, Christian, GALETTA, Steven L, RADUE, Ernst-Wilhelm, LUBLIN, Fred D, WEINSTOCK-GUTTMAN, Bianca, WYNN, Daniel R, LYNN, Frances

Get full text

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes by Coles, Alasdair J, Fox, Edward, Vladic, Anton, Gazda, Suzanne K, Brinar, Vesna, Selmaj, Krzysztof W, Bass, Ann Doan-Do, Wynn, Daniel R, Margolin, David H, Lake, Stephen L, Moran, Susan, Palmer, Jeffrey, Smith, M Shelton, Compston, D Alastair S

“…Alemtuzumab is a humanised monoclonal antibody that depletes lymphocytes, causing long-term immunomodulation. In a 3-year, rater-blinded phase 2 study (the…”
Get full text

A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota by WYNN, D. R, RODRIGUEZ, M, O'FALLON, W. M, KURLAND, L. T

“…A review of multiple sclerosis (MS) case reports, using the unified record system at the Mayo Clinic for the Olmsted County population, revealed age- and…”
Get full text

Update on the epidemiology of multiple sclerosis by Wynn, D R, Rodriguez, M, O'Fallon, W M, Kurland, L T

“…Neuroepidemiology has been important in providing clues about the cause and pathogenesis of multiple sclerosis. In this review, we update the incidence and…”
Get more information

Epidemiology of MS by Rodriguez, Moses, O'Fallon, Michael, Kurland, Leonard T., Wynn, Daniel R.

Get full text

Terminal component of complement (C9) in the cerebrospinal fluid of patients with multiple sclerosis and neurologic controls by RODRIGUEZ, M, WYNN, D. R, KIMLINGER, T. K, KATZMANN, J. A

“…We measured the concentration of C9 in the CSF and plasma of 93 consecutive patients referred for CSF examination in an outpatient multispecialty clinic. We…”
Get full text

A physical sign of bulimia by Wynn, D R, Martin, M J

Get more information